PMID- 23985254
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20181202
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 35
IP  - 4
DP  - 2013 Apr
TI  - [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative 
      rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
PG  - 268-72
LID - 10.3760/cma.j.issn.0253-3766.2013.04.006 [doi]
AB  - OBJECTIVE: The purpose of this study was to investigate the association between 
      single nucleotide polymorphism (SNP) of CCND1 A870G and acute adverse events 
      (AEs) in postoperative rectal cancer patients who received capecitabine-based 
      postoperative chemoradiotherapy (CRT). METHODS: Four hundred patients with stage 
      II and III rectal cancer received postoperative CRT of capecitabine with or 
      without oxaliplatin were accumulated and prostectively studied in this study. The 
      patients were randomly divided into two groups. Two hundred and twenty-eight 
      patients were treated with concurrent capecitabine and radiotherapy (Cap-CRT), 
      and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy 
      (Cap-Oxa-CRT). Adverse events were graded according to the Common Terminology 
      Criteria for Adverse Events, v. 3.0 (CTCAE v3.0). The genotype of CCND1 A870G in 
      the patients was detected by polymerase chain reaction-based restriction fragment 
      length polymorphism (PCR-RFLP) analysis. The associations between the SNP and 
      acute AEs were indicated by odds ratios (ORs) and 95% confidence intervals (CIs), 
      which were computed with logistic regression model. RESULTS: A total of 136 
      patients presented severe AEs. Among them the frequencies of the three genotypes 
      GG, GA and AA were 16.9%, 50.7% and 32.4%, compared with 24.6%, 48.1% and 27.3%, 
      respectively, among the patients without severe AEs. Diarrhea was the most common 
      AE, and severe diarrhea occurred in 109 patients. The frequencies of the three 
      genotypes GG, GA and AA were 15.6%, 47.7% and 36.7% among these patients, 
      compared with 24.4%, 49.5% and 26.1%, respectively, among patients without severe 
      diarrhea. Multivariate logistic regression analysis showed a 1.66-fold increased 
      risk for severe diarrhea in patients with AA genotype (95%CI 1.03 - 2.67, P = 
      0.038) compared with the cases with GG or GA genotypes. Stratified analysis 
      showed that in the Cap-Oxa-CRT group, patients with AA genotype showed a 
      2.34-fold increased risk for severe diarrhea (95%CI 1.16 - 4.76, P = 0.018) 
      compared with those with GG or GA genotypes, but in the Cap-CRT group, the SNP 
      was not associated with the risk of severe diarrhea. CONCLUSIONS: The genetic 
      polymorphism of CCND1 A870G might be a potential biomarker for predicting acute 
      AEs in postoperative stage II and III rectal cancer patients treated with 
      adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin.
FAU - Qiao, Yan
AU  - Qiao Y
AD  - Depatment of Etiology & Carcinogenesis, State Key Laboratory of Molecular 
      Oncology, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, Cancer 
      Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Ren, Hua
AU  - Ren H
FAU - Huang, Ying
AU  - Huang Y
FAU - DU, Zhong-li
AU  - DU ZL
FAU - Yu, Dian-ke
AU  - Yu DK
FAU - Jin, Jing
AU  - Jin J
FAU - Li, Ye-xiong
AU  - Li YX
FAU - Lin, Dong-xin
AU  - Lin DX
FAU - Tan, Wen
AU  - Tan W
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (CCND1 protein, human)
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 136601-57-5 (Cyclin D1)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Capecitabine
MH  - Chemoradiotherapy, Adjuvant/*adverse effects
MH  - Cyclin D1/*genetics
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - *Diarrhea/chemically induced/etiology
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Organoplatinum Compounds/administration & dosage
MH  - Oxaliplatin
MH  - *Polymorphism, Single Nucleotide
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Rectal Neoplasms/*genetics/pathology/surgery/*therapy
MH  - Risk Factors
EDAT- 2013/08/30 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/08/30 06:00
PHST- 2013/08/30 06:00 [entrez]
PHST- 2013/08/30 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3766.2013.04.006 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):268-72. doi: 
      10.3760/cma.j.issn.0253-3766.2013.04.006.